title: Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain.
abstract: We evaluated the possibility of using Yersinia pseudotuberculosis as a live vaccine against plague because it shares high genetic identity with Y. pestis while being much less virulent, genetically much more stable, and deliverable orally. A total of 41 Y. pseudotuberculosis strains were screened by PCR for the absence of the high pathogenicity island, the superantigens YPM, and the type IV pilus and the presence of the pYV virulence plasmid. One strain (IP32680) fulfilled these criteria. This strain was avirulent in mice upon intragastric or subcutaneous inoculation and persisted for 2 months in the mouse intestine without clinical signs of disease. IP32680 reached the mesenteric lymph nodes, spleen, and liver without causing major histological lesions and was cleared after 13 days. The antibodies produced in vaccinated animals recognized both Y. pseudotuberculosis and Y. pestis antigens efficiently. After a subcutaneous challenge with Y. pestis CO92, bacteria were found in low amounts in the organs and rarely in the blood of vaccinated animals. One oral IP32680 inoculation protected 75% of the mice, and two inoculations induced much higher antibody titers and protected 88% of the mice. Our results thus validate the concept that an attenuated Y. pseudotuberculosis strain can be an efficient, inexpensive, safe, and easy-to-produce live vaccine for oral immunization against bubonic plague.
authors.affiliation: Yersinia Research Unit, Institut Pasteur, 28 Rue du Dr Roux, Paris 75724, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Blisnick
authors.forename: Patrick
authors.initials: P
authors.lastname: Ave
authors.forename: Michel
authors.initials: M
authors.lastname: Huerre
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Carniel
authors.forename: Christian E
authors.initials: CE
authors.lastname: Demeure
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D001426:Bacterial Proteins / Q000235:genetics; D001769:Blood / Q000382:microbiology; D004269:DNA, Bacterial / Q000235:genetics; D005260:Female; D010861:Fimbriae, Bacterial / Q000235:genetics; D044404:Genomic Islands; D006801:Humans; D008099:Liver / Q000382:microbiology / Q000473:pathology; D008198:Lymph Nodes / Q000382:microbiology / Q000473:pathology; D051379:Mice; D010930:Plague / Q000517:prevention & control*; D016133:Polymerase Chain Reaction; D013154:Spleen / Q000382:microbiology / Q000473:pathology; D016019:Survival Analysis; D014613:Vaccines, Attenuated / Q000276:immunology; D037521:Virulence Factors / Q000235:genetics; D015010:Yersinia pestis / Q000276:immunology; D015011:Yersinia pseudotuberculosis / Q000235:genetics / Q000276:immunology* / Q000472:pathogenicity
chemical_list: D000907:Antibodies, Bacterial; D001426:Bacterial Proteins; D004269:DNA, Bacterial; D014613:Vaccines, Attenuated; D037521:Virulence Factors; C093313:Yersinia pseudotuberculosis-derived mitogen